We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Emergent Biosolutions (EBS) Com Stk USD0.001

Sell:$8.36 Buy:$8.39 Change: $0.08 (0.96%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$8.36
Buy:$8.39
Change: $0.08 (0.96%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$8.36
Buy:$8.39
Change: $0.08 (0.96%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Contact details

Address:
300 Professional Dr
GAITHERSBURG
20879
United States
Telephone:
+1 (240) 6313200
Website:
https://emergentbiosolutions.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EBS
ISIN:
US29089Q1058
Market cap:
$449.73 million
Shares in issue:
54.18 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Papa
    President, Chief Executive Officer, Director
  • Richard Lindahl
    Chief Financial Officer, Executive Vice President, Treasurer
  • Coleen Glessner
    Executive Vice President - Quality and Ethics and Compliance
  • Paul Williams
    Senior Vice President - Products Business
  • Jessica Perl
    General Counsel, Corporate Secretary
  • Simon Lowry
    Chief Medical Officer, Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.